Jamie Willows
@jamiekwillows
Followers
3K
Following
5K
Media
195
Statuses
2K
Renal/GIM consultant. Dad. Runner. Poker player. POCUS. #NSMC Intern 2021. @BukuRenal. Associate editor @NephJC.
Newcastle Upon Tyne, England
Joined January 2018
Semaglutide in patients with overweight or obesity and CKD without diabetes #ERA25 Semaglutide treatment for 24 weeks resulted in a clinically meaningful reduction in albuminuria in patients with overweight/obesity and non-diabetic CKD. https://t.co/6636FIFiET
nature.com
Nature Medicine - In participants with obesity and chronic kidney disease without diabetes, once-weekly administration of semaglutide 2.4 mg led to a reduction in albuminuria, body weight and...
0
2
7
@NephJC .@JeniferBrown @AnandVaidya17 we’d love to have authors at our discussion on Bluesky. Chat with @NephJC members tomorrow 2/11/25 at 9-10p EST. We have declared February (unofficial) Aldosterone month! @hswapnil @kidney_boy
0
2
4
APPLAUSE, APPLAUSE @VladoPerkovic @IgAN_JBarratt @BradRovin et al Iptacopan reduces proteinurie (PU) in IgA NP 🐘1: Is the effect additive to SGLT2I (low use in APPLAUSE) 🐘2: How long to treat with iptacopan? 🐘3: Will low PU be longterm renoprotective? https://t.co/awi5OWCNdY
2
26
74
Last one Tacro or MMF for steroid dependent of frequently relapsing nephrotic syndrome #KidneyWk
1
16
40
Nice summary from the @Oxford_NDPH team: “ …while empagliflozin continues to have some benefit after stopping treatment, the effects are smaller than when taking empagliflozin and short lived. Maximising the benefits of such medicines in #CKD requires long-term treatment.’
New evidence from the EMPA-KIDNEY trial has shown that people living with #CKD may benefit from longer-term use of -flozin medicines. The results are published in @NEJM and presented @ASNKidney by trial co-PI @willkidney. Read more 👉 https://t.co/QTBvABem0S
0
5
17
Welcome to #TenTweetNephJC ✳️10 tweets #NephJC catch-up ✳️ What is the best systolic BP in patients with high-risk CV comorbidities? We reviewed ESPRIT 👻 , in Lancet, comparing SBP 120 vs 140 mmHg in Chinese patients with vascular risks, DM & stroke. https://t.co/FoBfCDnCII
1
13
15
Nice review of one of my least favourite diagnoses. Not sure I believe it accounts for as many as 1 in 20 cases of urinary tract obstruction though…
0
3
12
T3d Long-term data (we’re talking 45 years+) on patients post nephrectomy suggesting little harm came from World War II veterans who had traumatic nephrectomy had similar survival rate, renal function, hypertension to that of aged-matched controls.#NephJC
2
3
8
Summary of latest publication looking at safety of kidney donation with 7 year follow-up.
#NephJC In my mind the key clinical implications. 1. Carefully selected standard criteria living kidney donors can be counselled that donating a kidney will not increase their blood pressure in the subsequent decade beyond what would be expected with normal aging.
0
0
3
#NephJC In my mind the key clinical implications. 1. Carefully selected standard criteria living kidney donors can be counselled that donating a kidney will not increase their blood pressure in the subsequent decade beyond what would be expected with normal aging.
14
7
20
Our #SMARTC collaborative meta-analysis is now in @TheLancetEndo: Data from >73,000 people across 12 trials provides the strongest evidence yet for combined use of SGLT2i & GLP-1RA to improve clinical outcomes in diabetes Download free for 50 days here: https://t.co/dRmbwQoZMD
2
44
76
#NephJC colleagues are amazing colleagues.
.#NephTwitter I’m inspired by @Tiff_Caza & @AnnaGaddy who each altruistically donated a kidney!! I’m in my 30th year as a T1DM (diagnosed in my 1st year of med school), 🤔so they won’t take my kidney… but I did donate my boat to the @nkf #NationalLivingDonorLegislation
0
0
1